SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (17292)3/12/1998 9:41:00 AM
From: Bryce Elkins  Respond to of 32384
 
FUGAZI - CNBC, David F., just reported that the Government may lift Medicare reimbursement rates for dialysis patients which could lift sales of epogen (sp), an Amgem product.

Ble



To: Hippieslayer who wrote (17292)3/12/1998 9:43:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
AMGN is up 4 on reports that Medicare reimbursement procedures for Epogen will change. I don't know the details, but since LGND has an Epogen and Neupogen program, good news on either should bode well for LGND, long term.



To: Hippieslayer who wrote (17292)3/12/1998 10:06:00 AM
From: tonyt  Respond to of 32384
 
> I don't believe this move up is "buy on the rumor, sell on the news" as was
> the case last time.

There has been discussion of the NDA, so don't rule out this possibility.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News